Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GL to you also - we all have different trading styles and have to each find ways of narrowing down the tickers we may choose to trade
np, un-marking the board. gl, it was over 100k yesterday.
Scanned a lot of tickers with potential to pick up EOD. Will reassess the list at 3:30 and make decisions from there:
NASDAQ:ACRX, OTCBB:CNTO, NASDAQ:ICLD, NYSE:INVN, NASDAQ:FREE, NASDAQ:DRYS, AMEX:ONVO, NYSE:VJET, NASDAQ:AMBA, NYSE:NQ, NASDAQ:CMGE, NASDAQ:UBNT, NASDAQ:HIMX, NASDAQ:WPCS, NYSE:USU, NASDAQ:QDEL, NYSE:TWTR, NYSE:XON, NASDAQ:TWGP, NASDAQ:GALE, NASDAQ:NTWK
At .03 a share, 1M traded is only $30K in total dollar volume - I can't trade shares at such low dollar volume. See the intro to this board - I stick with the top traded tickers on the OTC for the day only.
Over 100k trading volume yesterday? Check back soon and see what i was talking about. GL and Happy New Year!
Note for market hours today - Some investors and traders will welcome in the new year with an abbreviated trading session on Tuesday, Dec. 31. Others will have to tough it out to the end of the normal trading day before uncorking the champagne.
Stocks, including the New York Stock Exchange and Nasdaq, will close at their regular time of 4 p.m. Eastern.
The bond market will observe a 2 p.m. recommended close from Sifma, though there is no official market close.
Oil and gold will both settle at their normal times: 1:30 p.m. for gold, and 2:30 p.m. for oil, according to NYMEX.
Had another big morning today - December is now my best month since May, and May was very high b/c of the easy money from the FNMA run. My scanners have done very well lately picking up tickers that will gap and run the following day - will be interesting to see if I can maintain this momentum into January. I think the market will stay hot in January, so should be possible.
Dollar volume is too low on this one for my. CNTO is the best ticker on the OTC right now (of course, every OTC pick is extremely short-term)
My scanner picked up these ones to watch after 3 to see if they are still running (from the OTC, watching AMBS and CNTO):
CLEARSIGN COMBUSTION... CLIR 11.28 +0.14 (1.25%) 99.38M 102,729.00 12 12 11.1635
Amyris Inc AMRS 5.65 +0.42 (8.03%) 430.93M 758,080.00 5 5.75 4.95
Kandi Technologies... KNDI 12.45 +2.11 (20.41%) 460.01M 6.45M 12.23 12.63 11.5
500.com Ltd WBAI 35.54 +0.70 (2.01%) 1.95B 374,028.00 34.9 39.42 34.9
BIOLASE Inc BIOL 3.03 +0.43 (16.54%) 106.48M 5.22M 3.15 3.55 2.97
InterCloud Systems Inc ICLD 17.09 +1.89 (12.43%) 109.48M 1.82M 16.48 17.8194 16.25
Vanda Pharmaceuticals... VNDA 12.72 +0.53 (4.34%) 422.11M 248,064.00 12.22 12.7599 12.2101
CytRx Corporation CYTR 5.93 +0.67 (12.74%) 248.96M 5.87M 5.46 6.3 5.45
Acceleron Pharma Inc XLRN 35.94 +0.69 (1.96%) 1.01B 61,626.00 35.58 37.6599 35.58
Pointer Telocation... PNTR 11.67 +0.21 (1.84%) 64.84M 69,644.00 11.63 12.1 11.46
AirMedia Group Inc (ADR) AMCN 1.90 +0.02 (1.06%) 116.00M 818,113.00 1.9 1.95 1.85
InvenSense Inc INVN 19.42 +1.38 (7.65%) 1.70B 3.63M 18.87 20.28 18.7
China Finance Online... JRJC 5.19 +0.19 (3.80%) 115.15M 502,388.00 5.17 5.48 4.95
Perceptron, Inc. PRCP 13.61 +1.61 (13.46%) 120.25M 314,168.00 12.93 13.93 12.5
Real Goods Solar, Inc. RSOL 3.03 +0.22 (7.83%) 91.59M 2.96M 2.9 3.08 2.82
Trina Solar Limited... TSL 14.07 +0.92 (7.00%) 1.12B 3.21M 13.59 14.25 13.56
Canadian Solar Inc. CSIQ 30.35 +1.16 (3.97%) 1.31B 1.56M 29.3 30.7 29.29
Centor Energy Inc CNTO 1.34* +0.24 (21.82%) 92.06M 531,759.00 1.19 1.34 1.18
AMARANTUS BIOSCI INC AMBS 0.0879* +0.0147 (20.08%) 40.84M 9.37M 0.0724 0.0925 0.0724
Jazz Pharmaceuticals... JAZZ 127.74 +4.45 (3.61%) 7.12B 189,974.00 123.69 128.096 123.5201
Andatee China Marine... AMCF 1.77 +0.09 (5.36%) 17.45M 89,551.00 1.75 1.785 1.65
Crocs, Inc. CROX 15.66 +2.33 (17.48%) 1.38B 8.32M 14.95 15.85 14.75
Tetralogic Pharmaceutica... TLOG 9.52 +1.03 (12.13%) 194.84M 155,664.00 8.98 9.8 8.75
Of the tickers below, VISN sure has been on an incredible run. I will check this one EOD to see if the momentum holds up.
I was traveling Friday and this is the first day since I can remember that I don't own any tickers at open. I may try to catch a runner after open; will be looking at the following PM movers:
Pre Market Movers
Top Gaining Stocks
Price %Change
KNDI Kandi Technologie... 11.90 15.09%
CROX Crocs Inc. 14.75 10.65%
BIOL Biolase, Inc 2.87 10.38%
CYTR Cytrx Corporation... 5.70 8.37%
PRCP Perceptron Inc. 12.99 8.25%
TSL Trina Solar Ltd. ... 14.05 6.84%
THLD Threshold Pharmac... 5.00 6.61%
DX Dynex Capital Inc... 8.50 5.20%
VISN Visionchina Media... 32.80 5.13%
RIBT Ricebran Technolo... 5.50 4.76%
NMM Navios Maritime P... 19.99 4.60%
PICK Ishares Msci Glob... 20.46 4.53%
HTHT China Lodging Gro... 31.96 4.51%
ALGN Align Technology ... 59.70 4.37%
YGE Yingli Green Ener... 4.98 4.18%
TUR ishares Msci Turk... 47.27 3.89%
JGBS Powershares Db In... 19.97 3.85%
ATHM Athm 36.25 3.84%
JDSU Jds Uniphase Corp... 13.50 3.61%
CYOU Changyou.com Limi... 32.71 3.55%
Top Losing Stocks
Price %Change
CANF Can-fite Biopharm... 5.42 -33.90%
CSTE Caeserstone Sdot-... 38.20 -20.86%
HPJ Highpower Interna... 2.08 -19.38%
WPCS Wpcs Internationa... 2.19 -13.44%
MYGN Myriad Genetics I... 20.95 -13.21%
XRS Tal Education Gro... 20.48 -6.18%
JNUG Direxion Daily Ju... 14.50 -4.86%
LONG elong Inc. 19.01 -4.76%
TWTR Twitter Inc 61.16 -4.06%
CETV Central European ... 3.62 -3.98%
AMTD TD Ameritrade Hol... 29.00 -3.97%
WX Wuxi Pharmatech I... 36.03 -3.97%
GSVC Gsv Capital Corp.... 11.76 -3.92%
CTB Cooper Tire & Rub... 22.10 -3.75%
AMC Amc Entertainment... 19.42 -3.57%
NUGT Direxion Daily Go... 27.05 -3.39%
FREE Freeseas Inc 2.45 -3.16%
VIPS Vipshop Holdings ... 81.56 -3.08%
WAG Walgreen Co. 55.75 -2.93%
OXBT Oxygen Biotherape... 4.70 -2.89%
Welcome to the January Effect
by Rob Goldman
We talk a lot about seasonality because most investors' gains occur during big but short runs in the market, and oftentimes, these big runs occur from the last week of December through January of the upcoming year. This year it is a little different than most because of the big moves already recorded in the Russell 200 Index (over 33% year to date) and its surprisingly strong upward momentum in recent days. Some market watchers view this recent performance as a sign that a seasonal trend/rally called the January Effect may have already begun. However, we believe it is representative of a narrow rally rather than the commencement of the January Effect since it has not been a scenario where a rising tide lifts all boats. Instead, we believe that we have experienced a small Santa Claus rally that will morph into a sustained and broad movement.
There are multiple definitions associated with the January Effect and its related Santa Claus rally moniker. In a nutshell, the January Effect is an historical Wall Street moniker for the belief that small-cap stocks outperform large caps from January through June, with the trigger based upon catalysts mentioned above. In fact, this event has occurred for 28 of the past 34 years, which is an 84% accuracy rate!
To read more click here >> or visit http://www.thestockjunction.com
VISIT OUR SPONSOR
Triple your dividends with one stock -- starting TODAY, Dec. 27th!
With so many investors grabbing up shares of blue chips, yield is getting hard to come by. In fact, the average yield of the Dow has sunk to 2.1%. But our group of investors isn't worried. We're collecting big monthly dividends... up to $550 every 30 days... from a little-known investment that yields a whopping 12%! If you'd like to tap into this income stream, and earn up to triple the dividends of even the best blue chip, click here for our full report on this opportunity.
True Wall Street Stories, Part I
by Rob Goldman
At the end of the year, as everyone winds down their workload, I have always felt it is an opportune time for a lighthearted teaching moment or two. There are things that occur behind the scenes that are bizarre and with this knowledge in hand you can find ways to either save yourself some money, or make a few bucks on a quick trade or two.
Without further ado, I give you a snapshot of a true Wall Street story that highlights what can happen to a stock when an ill-fated rumor makes its way to investors. I am sorry I cannot divulge the names of the parties involved. The names have been omitted to protect the innocent.
Loose Lips Sink Ships
When I was working as an analyst at Piper Jaffray, I covered a stock with a $500 million market cap that had a huge market share in its major product lines. One of the largest mutual fund companies in the country owned 10% or more of the stock and I routinely gave the mutual fund manager that owned the stock in his fund updates on the company and my channel checks in the industry. I even set up conference calls with customers in China for this important client. Naturally, I also covered the stock's biggest competitor, which frankly was a company that had a market cap a mere 10% of the bigger one.
To read more click here >> or visit http://www.thestockjunction.com
I love sector rallies - keep an eye on the rare earths to see if they can keep moving on Monday:
NYSE:MCP NYSEMKT:QRM NYSEMKT:REE NYSEMKT:AVL NYSEMKT:TAS
NVIV and AMBS may have more potential on Monday
I have traded this one in the past. It is a p&d ticker. If another promo starts up, I will consider it - I don't bother playing these tickers when volume is low.
HSOL looks interesting - I love tickers rallying off recent crashes. Made a lot off of the IMUC bounce recently, for example.
Hey Doc what about some ewsi chart looks like a huge rebound with big news coming in jan.
hey buddy check out HSOL $2.63, just bought some
I have not been posting over the holidays but have been trading between family visits. Funny enough, it has been one of my best weeks of the year. As you all know on this board, I have been trading the shippers all year - well yesterday, Christmas came twice and they exploded like pumped penny stocks. The rally is still strong so keep an eye on them. I will take some more profits in the morning gapup, but will likely hold some positions in DRYS and FREE. FREE and NEWL are going to pay me nice at open, but not sure how today will go. If the rally continues into close, I suggest loading up after 3:30 for another big gap on Monday. I will use a rolling stop on my other shipping tickers such as EGLE and NM. Not at home right now and don't have time to watch all day but this should be another exciting one:
--------------------------------
Shipping stocks becoming unstoppable: Navios Maritime (NM), Baltic Trading Ltd (BALT), NewLead Holdings (NEWL), Eagle Bulk Shipping (EGLE), Genco Shipping (GNK)
Shipping stocks extended impressive run on the back of multiple catalysts. The Baltic Dry Index has hit 2,277 points. The market has started to take notice of the recovery in the industry and it looks like the shipping companies are again going to make a comeback.
Genco Shipping & Trading Limited (NYSE:GNK), Euroseas Ltd. (NASDAQ:ESEA) and Box Ships Inc (NYSE:TEU) each gained more than 10% while Baltic Trading Ltd (NYSE:BALT) added 4.8%, all extending gains after Maxim Group analyst Noah Parquette wrote in a note to investors that the dry bulk sector is at the beginning of a cyclical upturn.
The great news for the global shipping market is that rising demand for oil and refined products within Asia has led tanker rates to a three-and-a-half year high. What’s more, the rate for Jones Act tankers also hit an all-time high last week, as increasing domestic US oil output squeezes the market for US flagged vessels, Under the Jones Act only US flagged vessels are allowed to transport cargo between US domestic ports.
As a SA contributor reported “the shipping industry has been under immense pressure over the past five years due to the slowdown in the global economy and trade. There were some industry specific issues as well, such as oversupply to the operators resulting in record low shipping rates – this might have been sustainable if the global economy were in a boom; however, a recessionary environment coupled with oversupply of vessels is a recipe for disaster, which is exactly what happened”.
It is also believed that along with rising day rates and increasing demand, the number of new tankers and drybulk ships entering the global fleet has begun to fall, ending several years of market oversupply.
The dry bulk industry climbed following a broad-based rally on Tuesday, encouraged by a report that showed American companies were investing in their businesses at the fastest pace since January.
On Thursday, Navios Maritime Holdings Inc. (NYSE:NM) and Baltic Trading Ltd (NYSE:BALT) marked their new highs whereas NewLead Holdings Ltd (NASDAQ:NEWL) 35.86% and Eagle Bulk Shipping Inc. (NASDAQ:EGLE) rose 20.49%.
Tags: BALT, Baltic Trading Ltd, Eagle Bulk Shipping, EGLE, Genco Shipping, GNK, Navios Maritime, NEWL, NewLead Holdings, NM
Funny, before even reading this I had bought XOMA today
Keep an eye on XOMA / IDRA (my 2 new finds after HALO). HALO is gonna go higher IMO, but in due course of time, will become less volatile and thus, not good for day/swing trading.
XOMA and IDRA are still cheap - Baker Bros plays - I posted about XOMA a while back when it was $4 - Now $6+.
I am still waiting on NBG to take off (as I remain sidelined from active trading) - Warrant date end of Dec - Some catalysts after that.
How to Trade Next Week
by: Rob Goldman
December 20, 2013 10:30am EST
Trading stocks during Christmas week can be lucrative and it can also be a bit tricky. Stocks that trade on the OTC markets have been especially weak of late in terms of volume and price performance. In fact, I can’t remember the last time it has been this way. Perhaps it has something to do with how the calendar sits this year as market makers see more activity in NASDAQ-listed stocks and don’t want to be caught short during the holidays. So, they short stock only to cover later as buying comes in.
With all of this in mind, what does one do to be so successful that a loud proclamation of "Merry Christmas" is in order, rather than a muttering of “Mary Franklin?” Here are some tips to serve as a stocking stuffer.
Keep Your Routine
If you are a day trader or enjoy trading frequently, continue to do so. If you monitor passively, do not materially change your schedule. Real opportunities occur during this time of year, which is why trading at year-end is often referred to as a Santa Claus rally. The weather often has an effect this time of year. If there is a lot of snow or even warm weather across much of the nation, it puts people in a good mood, which also plays to the upside. After all, there is still a large element of psychology in the stock market. Bad and dreary weather can be a drag on you and stocks.
Watch Your List, Check It Twice
We all have stocks on a watch list but on which we have not yet pulled the trigger. Keep a close eye on it. You are likely not the only one watching these stocks. If there is even a small modicum of strength in a specific stock, it is probably a good buy.
Be Nimble and Quick
Don’t be afraid to buy stocks, even those that have some weakness for the reasons we cited above. This time of year a rising tide can lift all boats. I know a number of people who save up some “play money” this time of year and put it to good use. Small retail, technology and industrials are always good targets this time of year, as are select biotechs that are in the midst of consecutive up days.
Use Time Effectively
Using this time for research or portfolio and stock comparisons, etc. may set you up for a strong start to 2014, or eliminate losses. We all need time to take stock in our stocks, and this is as good a time as any.
Plan Your Selling
It is basically too late to sell for year-end purposes at this juncture. But, planning on selling current and future positions is always a great idea. For example, stocks bought at the end of the year are usually good sell candidates sometime during the second week of the year. This is especially the case if the trading on Jan. 2 is strong and ends up being a heavy up-day; it bodes well for the future. Therefore it may not be a bad idea to buy short term calls on an index with the intention of selling it early in the year. Just watch out for the premiums.
They are still looking strong - this keeps up, I will load up again around 3:40 for an AM run tomorrow
Nice,made some coin on FNMA from 2.70s
I was having an off week until I made it all back this morning with FMCC - beauty play, for some reason, off the bat, it ran much slower than FNMA so I loaded up as much as possible and then flipped once it caught up. Easy money.
Lol,I'm wondering if he's in other paid chats and gets ideas from them and then sells it to the paid 'regulars'.
Oh right - he calls it the "irregulars" - no, I don't pay for it. Can't imagine it is worth paying for, but not sure what it involves so you would have to look up what others say. I like the free material for occasional ideas.
Yea I seen that thanks,but there is a paid Membership also.Just wondering if you paid or not?
No, it is free. Anyone can sign up to "stock gumshoe" for free.
Alliance Creative Group (ACGX) Reports Revenue of $2,656,880 and Gross Profit of $689,488 for Q3 of 2013. (.0012)
OPK. call options or the stock. feel this could be a easy trade
Dr Frost will be on wall street tuesday. he is pissed at parkland negative 45 page report
also jim cramer loves opk. bet cramer has frost on mad money this week
AGEN-news coming-improved survival brain cancer-up 20% PM.
AFYG-looks like this was or still is a Flex Nation alert from last month at .08. It was alerted yesterday by BIG Investments at .12. Trade accordingly.
Evening,
Big Investment llc is alerting AFYG as a week long pick.
Will watch tomorrow.
NTEK-lots of interest on Ihub over weekend-lets see if it gets the volume tomorrow.
PennyStocksForever.com does its best to bring you accurate information but errors may and sometimes do occur. Always do your own research before investing. PennyStocksForever.com is not a licensed financial advisor. This is a paid for marketing newsletter which will state compensation, if any, for the specific company being marketed in the disclaimer at the end of this newsletter, this is not a solicitation or recommendation to buy or sell securities.
My New Report on PRDC.
I wanted to get the ticker out to you early this weekend so you can start your research. I will send you more information on PRDC tomorrow (Sunday).
Consider this an early Christmas present.
Here is a video about what PRDC does:
Keep an eye on CALL magicJack VocalTec Ltd Nasdaq on Monday - 50% of the float short - on the top shorted list; rallied big EOD Friday. May carryover.
Same deal with NQ
I have noticed this promoter touting a lot of the same stocks I have been trading (in particular, big board stocks). I am going to watch them for a bit and see if they can maintain a steady stream of good picks: http://bluehorseshoestocks.com/
NTEK-moved up a little more today-company released a PR late in trading, stating their NP-1 set box is in prod and it appears the manuf. is Foxconn. Shipments start next week. This one is going to get very interesting next week. Projected orders for 2013 for the NP-1 is 100k units at $299.00 a unit.
Still holding some HALO. Will be trading on Monday.
Well, my good morning also ended well so the kids are lucky as I will be in a charitable mood when I Christmas shop this weekend (will probably do it all on Amazon - I hate malls). I road the Twitter rally for some gains. Into close, I held DRYS, FREE, ARCW, FCEL, TRLA, and WBAI. The shippers were on fire again today - I still watch the shippers everyday as they continue to spike every now and again and it almost always carries over to the next trading days open. FREE, an old favourite, was the runner of the day - it had been beat up bad since the split and was in perfect territory for a pop. I hold no OTC tickers as nothing looked good to me in power hour. I was watching PCVT, but its rally finally ended it seems. I have some ads for a new promo ticker I will post when I get. I also would have picked up some NMBL - IPO'd today - but my damn broker said I had to call in the order so I didn't bother and left some accrued gains on the table. That will be one to watch Monday - IPOs are always fun to trade.
This week, I realized I need to stop holding flash-in-the pan one hit wonder tickers overnight (basically, those on the top Nasdaq gainers list for a day or two during one week of the year). Gave up a lot of EOD accrued gains in morning gap downs this week. For now on, overnight, I will only hold tickers I know well that have a strong chart and gapup history. I overestimated the ability of rallies in the last 15 minutes to carryover to the next day - sometimes it is best to just dump those tickers before close, especially when volume is thin.
Have a good weekend.
CLSN 4.31 ,, $4.50 break should give it a magnet pull to $5
Had my first big morning of the week - been a crappy week; I am even now. Oh well - Friday is always good. I will be hunting for gapups EOD but am all sold out for now. I will be watching my morning winners EOD as they may have more to give:
NASDAQ:PLUG, NASDAQ:FCEL, NYSE:VJET, NASDAQ:ARCW, NYSE:DDD, NASDAQ:SSYS, NASDAQ:MACK
Merrimack Announces Encouraging Clinical Data From Expanded Phase 1 Study of MM-302 for the Treatment of Advanced HER2-Positi...
Print
Alert
Merrimack Pharmaceuticals, Inc. (MM) (NASDAQ:MACK)
Intraday Stock Chart
Today : Friday 13 December 2013
Click Here for more Merrimack Pharmaceuticals, Inc. (MM) Charts.
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced Phase 1 clinical trial results for MM-302, a novel HER2-targeted liposomal doxorubicin for the treatment of advanced HER2-positive breast cancer. Primary objectives for the trial are to assess the safety of MM-302 as a monotherapy and in combination with trastuzumab, as well as to determine the Phase 2 dose for MM-302. Data were presented at the 2013 San Antonio Breast Cancer Symposium, Dec. 10-14, 2013 in San Antonio, Texas.
Anthracyclines, particularly doxorubicin, have been an effective component of breast cancer treatment for decades, though their use is ultimately limited by cardiac toxicity. These cardiotoxic effects limit the use of traditional anthracyclines in combination with targeted therapies, such as trastuzumab, for treatment of HER2-positive breast cancer. MM-302 is specifically designed to address this issue by delivering doxorubicin to tumor cells overexpressing HER2, while minimizing uptake into normal cells, including those of the heart.
In this ongoing Phase 1 study, patients treated with MM-302 showed no signs of clinical decline in cardiac function. The most common adverse events were fatigue, nausea and decreased appetite; the rates of these events were consistent across MM-302 as a monotherapy and in combination with trastuzumab. Results from the trial also showed that patients treated with MM-302 as a monotherapy at doses of 30, 40 and 50 mg/m2 had an estimated progression free survival (PFS) of 5.6 months (95% CI: 2.8-10.9 months) and a clinical benefit response rate of 37%. Of note, 5 of 9 patients who had not been previously treated with anthracyclines had a PFS of greater than 9 months.
"We are pleased with the data for this trial and the preliminary safety profile for MM-302, particularly in regards to cardiac toxicity," said Ulrik Nielsen, Chief Scientific Officer at Merrimack. "These results are encouraging for the development of our nanoliposomal technology platform, and an important step towards successfully establishing the safety and activity profile of MM-302 in the HER2-positive breast cancer population."
A Phase 2 study for MM-302 is being planned in patients with HER2-positive breast cancer.
METHODOLOGY AND RESULTS
Assessment of Safety and Activity in an Expanded Phase 1 Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced HER2-positive (HER2+) Breast Cancer (Abstract #P4-12-29)
Safety of MM-302
• To evaluate the safety and tolerability of MM-302 both as a monotherapy and in combination with trastuzumab, 47 patients with histologically confirmed HER2-positive metastatic breast cancer were included in the analysis. Patients received a median of 4 prior therapies for metastatic disease.
• The study first used a standard 3 + 3 dose escalation design for the monotherapy to determine a potential Phase 2 dose of MM-302. Patients were enrolled across 5 dose levels ranging from 8 mg/m2 to 50 mg/m2 given every 4 weeks. Expansion cohorts were performed at 40 and 50 mg/m2 for a total of 12 patients at each dose. Additional patients were then enrolled in arms receiving MM-302 plus trastuzumab.
• Overall, MM-302 was well tolerated. As a monotherapy, the most frequent all-grade adverse events were fatigue (65%), nausea (59%) and decreased appetite (41%). The addition of trastuzumab did not appear to increase the incidence of adverse events observed with the monotherapy alone.
• Neutropenia was the most common Grade 3/4 adverse event occurring in 7 patients (6 in the monotherapy arms and 1 in the combination arm). One dose limiting toxicity was observed (febrile neutropenia) and the dose was subsequently withheld; the patient went on to continue study treatment for 3 additional cycles.
• No clinically significant declines in left ventricle ejection fraction (LVEF) were observed in patients treated with MM-302 or MM-302 plus trastuzumab, including 8 patients who had been treated with lifetime cumulative doxorubicin in excess of 500 mg/m2.
Activity data
• Data was presented on 47 patients treated in the ongoing Phase 1 trial. Of the 27 evaluable patients who were treated with 30, 40 and 50 mg/m2 of MM-302 as a monotherapy, 1 patient achieved a complete response (CR), 3 patients achieved a partial response (PR), and 6 patients experienced stable disease (SD), resulting in a clinical benefit rate of 37%. Estimated progression free survival (PFS) was 5.6 months (95% CI: 2.8-10.9 months).
• In anthracycline-naïve patients treated with MM-302 as a monotherapy, 4 of the 9 patients achieved a CR or PR and 5 of the 9 patients had a PFS of 9 months or more.
• Of the 13 evaluable patients who were treated with MM-302 and trastuzumab, 4 were anthracycline-naïve. Of the 4 anthracycline-naïve patients, 2 achieved a PR and 1 experienced SD.
Imaging
• Tumor deposition and biodistribution of MM-302 was assessed in a subset of patients using 64Cu-labeled MM-302 and positron emission tomography (PET)/computed tomography (CT).
• Accumulation of 64Cu-labeled MM-302 was observed in metastatic lesions, including in the brain and bone.
About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six targeted therapeutic oncology therapeutics in clinical development. For more information, please visit Merrimack's website at www.merrimackpharma.com.
Forward-Looking Statement
To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any statements about Merrimack's strategy, future operations, future financial position and future expectations and plans and prospects for Merrimack, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. In this press release, Merrimack's forward-looking statements include statements about the potential effectiveness and tolerability of MM-302 as a monotherapy and in combination with trastuzumab in certain patient populations or subpopulations, its ability to develop a predictive diagnostic or imaging agent and its ability to translate clinical data into future clinical success. Such forward-looking statements involve substantial risks and uncertainties that could cause Merrimack's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals and other matters that could affect the availability or commercial potential of Merrimack's drug candidates or companion diagnostics. Merrimack undertakes no obligation to update or revise any forward-looking statements. Forward-looking statements should not be relied upon as representing Merrimack's views as of any date subsequent to the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Merrimack's business in general, see the "Risk Factors" section of Merrimack's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 8, 2013 and other reports Merrimack files with the SEC.
CONTACT: Investor Contact:
Geoffrey Grande, CFA
Merrimack
617-441-7602
ggrande@merrimackpharma.com
Media Contacts:
Debbie Tseng
Merrimack
617-441-7659
dtseng@merrimackpharma.com
Heather Gitlitz
Spectrum
202-955-6222
hgitlitz@spectrumscience.com
Social Media Stock's Bullish Reversal Signals 'Buy'
By Michael Kahn on December 12, 2013
Share on facebook Share on twitter Share on email Share on print Share on addthis
September was the month when many social media high-fliers topped out. Real estate community stock Trulia (NYSE: TRLA) was in the thick of things, running from roughly $15 at the start of the broad market's rally in November 2012 to a high of $52.71 in September of this year for a gain of more than 250%. Not too shabby.
When the pack turned, TRLA dropped like a stone, getting cut almost in half only three months later. However, such a steep drop breeds opportunity for short-term traders. And with many signs of capitulation, Trulia may have a nice bounce in the offing.
Capitulation is when the final bulls throw in the towel as they dump whatever they have at any price. We typically see a large range day to the downside after a long decline with exceptionally heavy volume. Sentiment drops to bearish extremes as everyone who was left to sell theoretically has already done so.
When there are no sellers left, it does not take much to get the stock moving higher. In fact, it can explode higher depending on how aggressive the bears have been.
In TRLA's case, more than 18% of the float -- or shares issued -- have been sold short. That is a big bet that prices will continue to move lower, and also a source of demand should the stock reverse to the upside. Short sellers must buy back shares they originally borrowed to sell, which creates demand and the potential for a short-covering rally.
In Thursday's trading, TRLA scored a bullish reversal to the upside. And volume was more than five times average, indicating a huge rush to get into this stock.
As for technicals, TRLA was indeed oversold by traditional measures such as the Relative Strength Index (RSI). It was also as much as 41% below its 50-day moving average this week, which is huge for any stock. The case that the stock was overextended to the downside is easy to make.
TRLA Stock Chart
For traders using traditional support and resistance, there is a support floor at current prices set by the bottom of its March-June trading range. Earlier this year, traders bought this level on at least seven occasions, and in technical analysis, the more times a level or structure is touched, the stronger it becomes. Demand seems to shoot up at $28 plus or minus a quarter, and this week was no exception.
How high can TRLA bounce? If we look at a simple declining trend channel, resistance at the upper border is near $34. The 50-day moving average is above that but it is falling and should meet the 200-day average in the $36.50 area. That puts the upside target somewhere in the middle near $35 if everything goes right. Since everything never goes completely right, we'll be a bit more conservative and shoot for something just below the trendline.
A new low would negate the reversal, especially because so much volume traded on the reversal itself.
Recommended Trade Setup:
-- Buy TRLA at the market price
-- Set stop-loss at $26
-- Set initial price target at $33 for a potential 13% gain in four weeks
Researcher Looking in Microscope
Next Article:
My Favorite Under $5 Biotech Could Soar 150% or More
My Favorite Under $5 Biotech Could Soar 150% or More
By Dave Goodboy on December 11, 2013
Share on facebook Share on twitter Share on email Share on print Share on addthis
The biotech sector remains the Wild West of stock investing. There is no other fully legitimate sector that has such intense price swings and volatility. The reason being is that the pharmaceutical and medical industries are trillion-dollar businesses. All it takes is a research team with a potentially valid idea to create a company and start the drug approval process.
Now, don't get me wrong. It's not an easy process, and most firms fail when it comes to getting product to the market. In reality, it's an onerous process to get a drug or medical device approved in the United States.
The process is extremely costly and time consuming, sometimes taking years and costing millions of dollars. However, if the company is successful, incredible wealth can flow to the owners and shareholders.
Every company has its ups and downs when it comes to the FDA approval process. This excitement and disappointment is what drives early-stage biotech share prices. I am not a scientist and do not claim to understand the nuances of drug approval. Fortunately, it is not critical to have a medical degree or Ph.D. to make money in biotech stocks.
A recent example of this extreme volatility is the biotech company Dendreon (NASDAQ: DNDN). The monthly price chart shows an explosion from below $5 to above $55, then back down below $5. It's a classic case of euphoria followed by disappointment.
DNDN Stock chart
This is just one example of literally hundreds of biotech companies that exhibit extreme volatility. Investors need to be aware and ready for the extreme moves inherent in biotech stocks before investing.
The true key to success is to diversify across a variety of early-stage biotechs rather than just one or two. This substantially increases your odds that one or more of your investments will be profitable enough to cover the losers.
While I firmly preach the importance of diversification across multiple biotech names, I am often asked what biotech I would invest in if I could only choose one. This is often a difficult question to answer, but right now, I do have a favorite biotech stock.
Merrimack Pharmaceuticals (NASDAQ: MACK) is by far on the top of my list right now as a stock that could easily triple from its current trading range. The company possesses all five of the critical characteristics crucial for biotech success.
These features are strong management, manageable debt, sufficient funding, a multi-product pipeline and products moving closer to approval. Remember, however, that companies can possess all five of these characteristics and still struggle for years.
MACK is very special as it not only possesses all five of the characteristics needed for success, it has two additional ones: insider buying and partnerships with large pharmaceutical companies. Those two bonus features are why MACK is my No. 1 biotech buy.
In the past three months, insiders, including the CEO and members of the board of directors, have collectively purchased 507,400 shares. When senior management has enough faith in their company to purchase large numbers of shares, it's a strong bullish signal.
The next special success characteristic of MACK is its partnerships with large firms. The company boasts a license and collaboration agreement with Sanofi (NYSE: SNY) related to its MM-121 product. In addition, MACK has a relationship with Actavis (NYSE: ACT).
These relationships put the company's cash and equivalents at $182.5 million at the end of the third quarter. This is more than enough to carry the company into 2015 without outside revenue. Remember, early-stage biotech companies are cash hungry and revenue short. Having a war chest of near $200 million gives MACK a huge advantage.
Technically, MACK has fallen from its recent high near $5 into a value buy zone. Buying here with a stop at $3.35 and an $11 target makes solid investment sense.
MACK Stock Chart
Recommended Trade Setup:
-- Buy MACK between $3.75 and $4.75
-- Set step-loss at $3.35
-- Set initial price target at $11 for a potential 132%-193% gain in 90 days
Disclosure: Dave Goodboy owns shares of MACK.
TWTR sure has had quite the bull run - I have flipped FB for sympathy profits but missed out on the TWTR run as it seems to start negative each morning and then pop out of no where. I am surprised how high it has gotten - has become a ticker I watch every day, along with FB and LNKD.
On the OTC, I am watching USOTC:FRMC, OTCBB:MDDD, USOTC:GSAT, USOTC:XUII, OTCBB:SOUL, OTCBB:NXTD, USOTC:WMIH. On the big boards, been flipping the 3D printers, PLUG and FCEL (a couple others also but they are one-offs)
HALO-nice call NT-picked up a starter yesterday at 12.83, up 3.6% already. Sweet.
Followers
|
59
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3274
|
Created
|
06/02/13
|
Type
|
Free
|
Moderator ThePennyDoctor | |||
Assistants Mouthhee ~ NT ~ |
The grim reality is short-term trading and especially day trading can be hazardous to your wealth. Ninety-two percent of day traders trying to scalp loose money. Only eight percent are successful. Out of the eight percent, only two percent of the day trading public make money on a consistent basis. Why do 92 percent of day traders fail and what makes eight percent successful? Let's take an honest look at day trading without the hype and emotion that surrounds the subject and find out what it takes to be a successful day trader.
We go to school, gain an education, become employed, or start our own business. We learn what we need to know to be successful, but nothing in our education or work experience provides the comprehensive knowledge or psychological control necessary for success as a trader. Unfortunately, it's human nature to assume that if we succeed in one area we will automatically succeed in another. Most people who enter the market with the idea of becoming traders have a feeling of invincibility, superiority, and no clue of what they are about to experience. The dream of quick money and financial success can very quickly become a living nightmare. The first step in becoming a successful trader is to understand why so many day traders fail. Answer the following questions:
If you're saying, "Not a chance," guess again. That is exactly what you are doing when you start trading for the first time. You must prepare yourself and realize that you are going to be up against the best traders in the world. Training, experience, psychological control, and a realization that your are not invincible or smarter than the market will lead you to success. Wall Street is paved with the bones of those who did not learn this lesson until it was too late.
Most new traders have the wrong focus. If money is your focus, you have little chance of success. Many new traders look at trading as a way to escape a job they hate. They know they have to make a certain amount of money to pay the bills and this becomes a psychological guillotine. When the trader fails to meet the goal, he begins to push trading beyond his true ability and skill. The result is a series of losing trades that could have been avoided if the trader had the correct focus. Your focus and the measure of your success should be based on following the trading plan, not money. If you follow the plan each day, you are a winner. If the focus is money, it leads to emotional decisions and emotional decisions lead to uncontrolled losses. Successful traders make decisions based on fact and analysis. Do this and money will follow if your methodology is a sound one.
The Mathematics Of Trading
Almost everyone has heard the term "cut your losses." Nowhere is this lesson more evident than in day trading. Statistics tell us that most new day traders lose over $21,000 dollars in their first three months of trading. If they use leverage the average loss rises to more than $45,000. Nothing supports the reasoning for not overtrading and cutting a loss more than an understanding of the mathematics of what it takes to recover from a previous losing trade. If you were down 15 percent, you would need to make 17.6 percent in the next trade to breakeven. This does not cover slippage or commissions so in reality you would have to do far better than 17.6 percent. Now, imagine making 30 trades a day and most of them losses. It has been my experience that it is extremely difficult to recover from any loss of capital above 25 percent for most traders. This is because it takes 33.33 percent to recover in the next trade. If a trader has allowed the trade to lose 25 percent they simply are not managing the risk. I have known traders to have 10 winning trades and lose it all by not managing the risk on two trades. The successful trader is ruthless about cutting a loss because they understand the mathematical relationship of trading. I have been in this business for a very long time and if I have learned one lesson it is this-once you enter a trade you are no longer a trader you are a risk manager. Never forget this.
Not Every Day
One of the interesting observations I have made over the years about day traders is that they have great difficulty not trading. Who ever said every day was a trading day was wrong. Only make trades that have a high probability of working out. This means that successful day traders make fewer trades and do not trade everyday. Look for strong trending market days and trade stocks that trend with that market.
Many day traders are addicted to the action and making money has little to do with their true reason for trading. These individuals are not traders, they are gamblers. Action addicts will lose as many times as necessary just for the adrenaline rush to win once. Most successful day traders make no more than three to five high probability trades per day. It has been my experience that if a trader makes over 18 trades a day, they are in all probability gamblers not traders. Successful day traders know that not everyday is a high probability trading day and overtrading can be hazardous to your wealth.
High Probability Screening
Most day trading cowboys will shoot at anything that moves. In most cases they walk into their trading room with no game plan other than to listen to the news and trade the momentary euphoric hype in the room. If this is your preparation for battle, your days are numbered and the following might appear on your head stone: "Here lies the bones of a day trading master. He was fast on the mouse but somebody was faster."
Screening for high probability profitability trades is of the utmost importance. We teach our students to quantify and select the three highest probability trades that have a reward-to-risk ratio of 2.5 or greater. The screening process looks for and selects the maximum momentum acceleration points on a given security. Out of a database of 500 stocks, our traders select the three highest probability profitability trades for the following day. Ninety-eight percent of a traders success is due to the work done the night or day before the trade occurs. Success in day trading means a lot of work and very few people will do the work necessary. Losers are always looking for the easy way out. Success is directly proportional to the amount of work you will do that no one else will.
What Kind Of Day Trader Are You?
One of the keys to successful trading is to understand that you are an individual and as an individual you have strengths and weaknesses. One reason that day traders have such a high percentage of losses is that they are trained to use a standard one-size-fits-all approach. Unfortunately this approach is a day trading style known as scalping. A scalper trades for small fractions of a point-from 1/16 to 1/8. This style of trading has a 92 percent failure rate. Most people do not have the psychological control or ability to successfully trade with this strategy. Another strategy known as intraday trend trading has a much better success rate. The intraday trend trader will stay in a trade until the trend reverses. This could take a few minutes or several hours. This style of day trading makes time your friend and enables you to trade for points instead of fractions. The trend trader is far less likely to be whipsawed out of a trade because the focus is on staying with the trend. Notice that I did not say momentum. Momentum is usually associated with scalping too close to the axis of volatility. This volatility is usually displayed on a NASDAQ Level II screen. Years ago this information was very useful for traders. Today it is not as important as it once was and in fact, professional traders use the day traders own out-of-date information about the Level II screen to lure scalpers to their doom. If you are trend trading intraday, Level II has less importance and your chance for success is far greater. Traders trading this style tend to trade much less and statistically have a more successful outcome. Successful traders identify what type of trader they are and do not try to trade a methodology that does not fit their personality.
What It Takes To Be A Successful Day Trader
A consistently successful day trader knows his or her success in not found in the box (computer software or hardware). Many times traders look for the answers in technology and it is not there. They blame technology for failure so their answer is to buy more technology. The answer is understanding and controlling your own emotion and taking responsibility for your own actions and making decisions based on analysis. If you are wrong, you do not personalize the loss, you just say "next." Successful traders know that losing is part of the cost of doing business. Great day traders know that you will never learn how to win until you first learn how to lose. How a trader psychologically handles loss many times determines success or failure. Success in day trading is most of all a mastery of one's self. This is not the get rich quick easy road to riches that some people think it is. It requires a commitment of time, money, and a willingness to work very hard.
Desire and working hard is not enough. You are going to need working capital. This is like any other business it takes money to make money. I suggest you have a minimum of $50,000 to $100,000. Many novice traders attempt to trade without being properly capitalized. Once you have the capital and begin to trade, never forget once you enter a trade you are no longer a day trader. Instead you are a risk manager. Trade only high probability trades and remember, every day is not a high probability trading day.
Probability of Market Going Up TommorowWant to trade successfully? Just choose the good positions and avoid the bad ones. Poor trade selection takes a heavy toll as it bleeds your confidence and wallet. You face many crossroads during each market day. Without a system of discipline for your decision-making, impulse and emotion will undermine skills as you chase the wrong stocks at the worst times.
Many short-term players view trading as a form of gambling. Without planning or discipline, they throw money at the market. The occasional big score reinforces this easy money attitude but sets them up for ultimate failure. Without defensive rules, insiders easily feed off these losers and send them off to other hobbies.
Technical Analysis teaches traders to execute positions based on numbers, time and volume. This discipline forces traders to distance themselves from reckless gambling behavior. Through detached execution and solid risk management, short-term trading finally "works".
Markets echo similar patterns over and over again. The science of trend allows you to build systematic rules to play these repeating formations and avoid the chase:
1. Forget the news, remember the chart. You're not smart enough to know how news will affect price. The chart already knows the news is coming.
2. Buy the first pullback from a new high. Sell the first pullback from a new low. There's always a crowd that missed the first boat. [This rule will save you a lot of money - very rare for new highs/lows not to be tested; don't buy at the peak or sell at the floor.]
3. Buy at support, sell at resistance. Everyone sees the same thing and they're all just waiting to jump in the pool.
4. Short rallies not selloffs. When markets drop, shorts finally turn a profit and get ready to cover. [This is key in Penny Land - short the promo just before the dump; it is too late after the dump hits.]
5. Don't buy up into a major moving average or sell down into one. See #3.
6. Don't chase momentum if you can't find the exit. Assume the market will reverse the minute you get in. If it's a long way to the door, you're in big trouble.
7. Exhaustion gaps get filled. Breakaway and continuation gaps don't. The old traders' wisdom is a lie. Trade in the direction of gap support whenever you can. [Also don't sell a gap that does not fill too early; use a trailing stop instead.]
8. Trends test the point of last support/resistance. Enter here even if it hurts. [Some of these are reptative aren't they - probably only need 10 "golden rules".]
9. Trade with the TICK not against it. Don't be a hero. Go with the money flow. [i.e., the trend is your friend.]
10. If you have to look, it isn't there. Forget your college degree and trust your instincts. [My graduate degree never helped me learn to trade the OTC. As i recall, my corporate finance professors always did crap in the markets by their own accounts.]
11. Sell the second high, buy the second low. After sharp pullsbacks, the first test of any high or low always runs into resistance. Look for the break on the third or fourth try.
12. The trend is your friend in the last hour. As volume cranks up at 3:00pm don't expect anyone to change the channel. [I also love morning power hour; I have always said I only need 2 hours of trading to make money, and they are at open and close - this is especially true on the OTC..]
13. Avoid the open. They see YOU coming sucker
14. 1-2-3-Drop-Up. Look for downtrends to reverse after a top, two lower highs and a double bottom.
15. Bulls live above the 200 day, bears live below. Sellers eat up rallies below this key moving average line and buyers to come to the rescue above it.
16. Price has memory. What did price do the last time it hit a certain level? Chances are it will do it again.
17. Big volume kills moves. Climax blow-offs take both buyers and sellers out of the market and lead to sideways action. [One of the reasons I focus on the power hours.]
18. Trends never turn on a dime. Reversals build slowly. The first sharp dip always finds buyers and the first sharp rise always finds sellers.
19. Bottoms take longer to form than tops. Greed acts more quickly than fear and causes stocks to drop from their own weight.
20. Beat the crowd in and out the door. You have to take their money before they take yours, period. [i.e. don't be greedy, but be early.]
Posts Today
|
0
|
Posts (Total)
|
3274
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |